- Home
- INMB vs ACOG Comparison
INMB vs ACOG Comparison
Compare INMB & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ACOG
- Stock Information
- Founded
- INMB 2015
- ACOG 2000
- Country
- INMB United States
- ACOG Canada
- Employees
- INMB N/A
- ACOG N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ACOG
- Sector
- INMB Health Care
- ACOG
- Exchange
- INMB Nasdaq
- ACOG Nasdaq
- Market Cap
- INMB 68.9M
- ACOG 80.3M
- IPO Year
- INMB 2019
- ACOG N/A
- Fundamental
- Price
- INMB $1.89
- ACOG $9.56
- Analyst Decision
- INMB Buy
- ACOG Strong Buy
- Analyst Count
- INMB 4
- ACOG 1
- Target Price
- INMB $9.53
- ACOG $20.00
- AVG Volume (30 Days)
- INMB 806.4K
- ACOG 72.2K
- Earning Date
- INMB 10-30-2025
- ACOG 08-14-2025
- Dividend Yield
- INMB N/A
- ACOG N/A
- EPS Growth
- INMB N/A
- ACOG N/A
- EPS
- INMB N/A
- ACOG N/A
- Revenue
- INMB $50,000.00
- ACOG $4,586,341.00
- Revenue This Year
- INMB $142.83
- ACOG N/A
- Revenue Next Year
- INMB $14,780.90
- ACOG $149.89
- P/E Ratio
- INMB N/A
- ACOG N/A
- Revenue Growth
- INMB N/A
- ACOG N/A
- 52 Week Low
- INMB $1.86
- ACOG $3.75
- 52 Week High
- INMB $11.64
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- INMB 31.89
- ACOG 60.33
- Support Level
- INMB $1.86
- ACOG $8.01
- Resistance Level
- INMB $2.00
- ACOG $8.34
- Average True Range (ATR)
- INMB 0.13
- ACOG 0.50
- MACD
- INMB 0.01
- ACOG 0.16
- Stochastic Oscillator
- INMB 7.41
- ACOG 96.67
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.